INTESTINAL DISTRIBUTION OF

SECRETIN
Hannah Gilliam-Vigh, M.Sc., Ph.D. student, Medicine student
Center for Clinical Metabolic Research, Gentofte Hospital, Denmark
Coauthors: Tina Jorsal, Sophie W. Nielsen, Julie L. Forman, Jens Pedersen, Steen S. Poulsen, Tina
Vilsbøll and Filip K. Knop
 Detailed map in
the healthy
SECRETIN & TYPE 2
DIABETES intestines
Enteroendocrine hormone released from the

Potential role in
duodenum
Released from S cells in response to gastric acids

Type 2 Diabetes
Binds to Secretin Receptor
Associated to reduced food intake

pathophysiology
Potentiate glucose-stimulated insulin release
Increased after Roux en Y gatric bypass operations
 METHOD

•Rhee et al. 2014

•12 individuals in each group
•Counseling, metformin or sulfonylurea
•Two days of double balloon enteroscopy
•Biopsies from anatomically well-
defined locations
•At every 30 cm jejunum and ileum

Variable Type 2 diabetes Healthy controls P-value

Sex (M/F) 9/3 8/4 1.00
Age (years) 51 (34 – 63) 50 (41 – 67) 0.66
BMI (kg/m2) 26.8 (23.7 – 31.5) 27.1 (20.3 – 30.8) 0.92
HbA1c (%) 6.5 (5.4 – 9.9) 5.3 (4.8 – 6.1) 0.01
HbA1c (mmol/mol) 48 (36 – 85) 34 (29 – 43) 0.01
Duration of type 2 diabetes 5.0 (1.0 – 9.0) - -
 RESULTS

Dark bars – Healthy controls

Light bars – Type 2 Diabetes

SCT – Secretin
SCTR - Secretin Receptor
 S cell density and SCT and SCTR
mRNA expression were abundant
in the duodenum and decreased
CONCLUSION along the small intestine

Very low levels of SCT and

SCTR mRNA and low S cell
numbers were found in the large
intestine

No significant difference in
individuals with T2D compared
to healthy controls were observed